Eli Lilly and Company (NYSE:LLY - Get Free Report) had its target price hoisted by equities researchers at Argus from $770.00 to $840.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Argus' target price points to a potential upside of 9.96% from the stock's current price.
Several other research firms have also recently issued reports on LLY. Barclays upped their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research note on Wednesday, February 7th. Truist Financial upped their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a "buy" rating in a research note on Wednesday, May 1st. Citigroup boosted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald restated an "overweight" rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday, April 30th. Finally, The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research note on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $769.53.
Get Our Latest Stock Report on LLY
Eli Lilly and Company Stock Up 0.8 %
Shares of Eli Lilly and Company stock traded up $6.19 during trading on Tuesday, hitting $763.89. The company's stock had a trading volume of 1,955,605 shares, compared to its average volume of 3,034,869. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a fifty day simple moving average of $760.79 and a two-hundred day simple moving average of $680.10. The company has a market capitalization of $726.01 billion, a PE ratio of 112.34, a P/E/G ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company's quarterly revenue was up 26.0% compared to the same quarter last year. During the same period last year, the business earned $1.62 EPS. Equities research analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current year.
Hedge Funds Weigh In On Eli Lilly and Company
Large investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its position in Eli Lilly and Company by 1.8% during the first quarter. Versant Capital Management Inc now owns 736 shares of the company's stock worth $573,000 after purchasing an additional 13 shares during the last quarter. Moseley Investment Management Inc. increased its position in shares of Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company's stock worth $3,027,000 after acquiring an additional 14 shares in the last quarter. CGN Advisors LLC increased its position in shares of Eli Lilly and Company by 1.4% in the first quarter. CGN Advisors LLC now owns 1,001 shares of the company's stock worth $779,000 after acquiring an additional 14 shares in the last quarter. Twin Peaks Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 2.0% in the first quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company's stock worth $559,000 after acquiring an additional 14 shares in the last quarter. Finally, Pitti Group Wealth Management LLC increased its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company's stock worth $1,271,000 after acquiring an additional 14 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
